Boehringer Ingelheim BioXcellence: Distinctive brand for the biopharmaceutical contract manufacturing business

Vienna/Austria, 27 June 2012 –With Boehringer Ingelheim BioXcellence the pharmaceutical company Boehringer Ingelheim set up an own brand for its biopharmaceutical contract manufacturing business.

Customer value has always been in the focus of the biopharmaceutical contract manufacturing business at Boehringer Ingelheim. The long history of more than 35 years in the field of biotechnology and a product track record of 19 customer products brought to the market show the company's commitment to this business. The new brand Boehringer Ingelheim BioXcellence unifies the experience, dedication and commitment of this biopharmaceutical contract manufacturing business towards customers and their projects and is also reflected in its mission – Producing Value.

"Our new brand Boehringer Ingelheim BioXcellence will help our customers and the market identify with the quality and reliability which has made Boehringer Ingelheim's biopharmaceutical contract manufacturing business one of the largest in the world," stated Simon Sturge, Senior Vice President Biopharmaceuticals at Boehringer Ingelheim. "We are very enthusiastic to live the new brand and our customers will experience that we have grown together to one global contract manufacturing organization.

"The new brand will be officially launched at BIO US in Boston, 18 – 21 June 2012, one of the most important conferences in the biopharmaceutical industry. Simultaneously with the new brand Boehringer Ingelheim BioXcellence the company also launches its new website which is dedicated to its contract development and manufacturing services. The customer friendly navigation and the comprehensive content of technical information and capabilities shows all that Boehringer Ingelheim BioXcellence can offer to its customers.

About Boehringer Ingelheim BioXcellence

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro.

Boehringer Ingelheim Biopharma Contract Manufacturing has now evolved into Boehringer Ingelheim BioXcellence. As a leading biopharmaceutical contract manufacturer with more than 35 years of experience – the company has brought 19 biopharmaceutical products to market. Boehringer Ingelheim BioXcellence offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production technology chain from DNA to fill and finish under one roof at its facilities in Biberach (Germany), Vienna (Austria) and Fremont (USA).

Boehringer Ingelheim BioXcellence can secure product supply throughout the entire product lifecycle—transferring customer projects at any stage, delivering to almost any scale and thereby makes outsourcing easy.

More information:

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)